The use of beta-adrenergic blockade in preventing trauma-induced hepatomegaly.
OBJECTIVE
The objective of this study was to test the hypothesis that hepatomegaly in burned children can be attenuated or reversed by blocking lipolysis and reducing free fatty acids delivered to the liver.


BACKGROUND
Accelerated lipolysis in severely burned children has been shown to play an important role in the accumulation of hepatic TGs. Severely burned children who survive 10 days or more after injury commonly have enlarged livers often twice or more normal size for their sex, age, and weight.


METHODS
Ninety-eight children, 2 to 18 years of age, with burns covering more than 40% of their body surface and who received either propranolol (beta-adrenergic blockade) or placebo were studied. Liver weights were measured by ultrasonic scanning. Body composition changes were identified by dual-image x-ray absorptiometry and validated by whole-body potassium-40 scintillation counting. Discarded abdominal cutaneous adipose tissue was collected before and after propranolol or placebo for microarray analysis.


RESULTS
In 80% of severely burned children studied not receiving propranolol, liver sizes increased by 100% or more while 86% of burned children receiving propranolol showed a decrease or no change in liver size over the same period of time after injury. Gene expression patterns of adipose tissue after propranolol treatment showed that all of the identified genes related to lipid metabolism were down-regulated.


CONCLUSIONS
Data reported here support the hypothesis that beta-adrenergic blockade can reduce delivery of fatty acids to the liver and hepatic congestion commonly found in severely burned children by inhibiting lipolysis and reducing hepatic blood flow.
Barrow
Robert E
RE
Department of Surgery, University of Texas Medical Branch, and Shriners Hospitals for Children, Galveston, TX 77550, USA. rbarrow@utmb.edu
Wolfe
Robert R
RR
Dasu
Mohan R
MR
Barrow
Laura N
LN
Herndon
David N
DN
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002056:Burns / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D002648:Child; D004750:Enteral Nutrition; D005260:Female; D006529:Hepatomegaly / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D011433:Propranolol / Q000627:therapeutic use*; D016038:Skin Transplantation; D013514:Surgical Procedures, Operative; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D011433:Propranolol